PHARMAUST LIMITED - Charts / Financials

Market Cap $87.55M Add to my watchlist

Healthcare

PharmAust is a clinical-stage biotechnology company developing new therapeutics for human... PharmAust is a clinical-stage biotechnology company developing new therapeutics for human health. The Company's segments include Corporate and Research. The Company is focused on repurposing monepantel for the treatment of neurodegenerative diseases, in particular amyotrophic lateral sclerosis (ALS) - the most common form of motor neurone disease (MND). The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway which plays a central role in cell growth and proliferation and in degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic protein is broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including motor neurone disease. The company successfully completed a Phase 1 study in monepantel as a treatment for ALS/MND with encouraging results. Monepantel has subsequently been accepted into the prestigious HEALEY ALS Platform Trial in the US. The company anticipates starting the Phase 2/3 study in H2 2024.More

RCE'S BREAKTHROUGH

Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department of Defense...

REFRESH

Last update - 15.23pm 20/09/2024 (20 minute delay)

Day
Open	17.0¢		Day High	18.0¢		Day Low	17.0¢
Daily Volume	210869

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
1	17.0¢	58823		3	18.0¢	154996

Directors & Senior Management

Dr. Michael Thurn	Chief Executive Officer, Managing Director, Director
Mr. John Clark	Chief Operating Officer
Dr. Nicky Wallis	Chief Scientific Officer
Ms. Fiona Milner	General Manager - Epichem Pty Ltd
Mr. Stefan Ross	Company Secretary
Mr. Sergio Duchini	Non-Executive Chairman of the Board
Mr. Marcus Paul Hughes	Non-Executive Director
Dr. Kathryn Macfarlane	Non-Executive Director

Data source: Refinitiv

(20min delay)
Last 18.0¢		Change 0.010(5.88%)		Mkt cap ! $87.55M

Open	High	Low	Value	Volume
17.0¢	18.0¢	17.0¢	$36.1K	210.8K

Buyers (Bids)

No.	Vol.	Price($)
1	58823	17.0¢

Sellers (Offers)

Price($)	Vol.	No.
18.0¢	154996	3

View Market Depth

No.	Vol.	Price($)
1	58823	0.170
8	285102	0.165
10	411812	0.160
10	715171	0.155
3	120660	0.150

Price($)	Vol.	No.
0.180	29411	1
0.185	130000	3
0.190	392233	6
0.195	484179	8
0.200	208866	10

Last trade - 16.10pm 20/09/2024 (20 minute delay)


Last 17.0¢		Change 0.010 ( 1.49 %)
Open	High	Low	Volume
16.5¢	17.5¢	16.5¢	246876
Last updated 15.23pm 20/09/2024 ?

PAA (ASX) Chart

PHARMAUST LIMITED - Charts / Financials

Directors & Senior Management

Buyers (Bids)

Sellers (Offers)

Top Stories